Skip to main content

Lab Notes: Endo acquires 6 product candidates for $35M; NiKang signs deal worth up to $218M

Marinus Pharmaceuticals resumes late-stage testing of its experimental seizure medication.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.